DDInter1269 DDInter690
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
Nateglinide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ethanol
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvoxamine
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Ethanol
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Perphenazine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Ethanol
Nateglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfinpyrazone
Sulfinpyrazone {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Ethanol
Nateglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aminoglutethimide
Aminoglutethimide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Ethanol
Nateglinide {u} may lead to a major life threatening interaction when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ethanol
Nateglinide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ethanol
Nateglinide {u} may lead to a major life threatening interaction when taken with {v} Enoxacin
Enoxacin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Ethanol
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Ethanol
Nateglinide {u} (Compound) binds {v} (Gene) PPARG
PPARG {u} (Gene) is regulated by {v} (Gene) GRIN3A
GRIN3A {u} (Gene) is bound by {v} (Compound) Ethanol
Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ethanol (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Ethanol (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Ethanol (Compound)
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Ethanol (Compound)
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ethanol (Compound)
Nateglinide may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ethanol (Compound)
Nateglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ethanol (Compound)
Nateglinide may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ethanol (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Ethanol (Compound)
Nateglinide (Compound) binds PPARG (Gene) and PPARG (Gene) is regulated by GRIN3A (Gene) and GRIN3A (Gene) is bound by Ethanol (Compound)